Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Site for A Phase 3, 4-Week, Parallel Group, Double-Blind, Vehicle- Controlled, Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis

Atopic Dermatitis: Phase 3 Double Blind, Vehicle-Controlled Study. Participation will last approximately 8 weeks. Topical cream will be applied once a day, Males/Females at least 6 years old with mild to moderate atopic dermatitis Atopic Dermatitis is a chronic inflammatory skin disorder affecting children and adults, with the majority presenting with disease of mild to moderate severity. The purpose of this study is to find out if the study medicine, ARQ-151 0.15% cream vs vehicle cream is safe for subjects with atopic dermatitis
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
All
This study is NOT accepting healthy volunteers
NCT04773600
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
History of Atopic Dermatitis for at least 3 months in subjects 6-17 years or age
History of Atopic Dermatitis for at least 6 months in subjects 18 years and older.
Willing to attend all study visits and follow directions
Exclusion Criteria:
Certain treatments for Atopic Dermatitits are not allowed; study coordinator will discuss
Subjects currently undergoing allergy testing
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA